To the Editor: Psoriasis management relies on long-term therapies that control symptoms and reduce disease manifestations. Apremilast is a safe and effective agent for treating psoriasis according to its randomized controlled trials (RCTs), ESTEEM 1 and 2.
1,2 However, it is important to evaluate apremilast's safety in real-world practice (RWP) because RCTs are primarily powered to measure efficacy. 3 Hence, institutions such as the US Food and Drug Administration often rely on real-world postmarketing safety surveillance when approving regulatory actions. 3, 4 We evaluated the short-term reasons for withdrawal and safety of apremilast in RWP compared with in RCTs. A retrospective review of 208 patients was conducted at 2 academic hospitals. The project was approved by the research ethics board of Women's College Hospital and Sunnybrook Health Sciences Centre. Patients with psoriasis who were treated with apremilast and at least 18 years old were included. Patients were permitted to use concurrent therapies alongside apremilast. Safety (reported adverse events [AEs]) and tolerability (withdrawal due to AEs) were assessed from baseline to week 16. The Pearson test was used to compare outcomes between patients in RWP and RCTs (P # .05 was considered significant).
Our results demonstrated that fewer patients in RWP reported 1 or more AEs than did patients in RCTs (58.7% in RWP vs 68.9% in an RCT [P ¼ .005]) (Table I). 1,2 However, many common AEs reported in RWP were shown in proportions similar to those reported in RCTs: diarrhea (P ¼ .624), headache (P ¼.298), and nausea (P ¼.447). In all, 39 patients in RWP withdrew treatment on account of AEs, and this number was proportionately greater than in RCTs (18.8% in RWP vs 5.3% in an RCT [P \ .001]) (Table II) . Accordingly, many AEs leading to withdrawal in RWP were reported in greater proportions than in RCTs: diarrhea (P ¼.001), nausea (P ¼ .004), and headache (P \.001).
These real-world findings support the apremilast RCT data. Most patients in RWP experienced mild-tomoderate AEs similar to those experienced by patients in RCTs: diarrhea (P ¼ .624), headache (P ¼ .298), and nausea (P ¼ .447). Moreover, we had no reports of tuberculosis reactivation, malignancy, opportunistic infections, or life-threatening AEs. In fact, the proportion of patients in RWP who experienced 1 or more AEs was lower than in RCTs (P ¼ .005). 1, 2 This may be explained by the fact that AEs were not actively elicited in RWP, as reflected by our lower proportion of reports of upper respiratory tract infection (P ¼ .003).
As expected, there were proportionately more withdrawals in RWP than in RCTs (P \ .001). The real-world AEs resulting in discontinuation paralleled those in RCTs but were reported in greater proportions: diarrhea (P ¼ .001), nausea (P ¼ .004), and headache (P \ .001). These larger withdrawal proportions can be attributed to several factors. First, most patients in RWP had insurance coverage, allowing them to easily switch medications. Second, patients in RCTs generally had more frequent clinical visits, which encouraged tolerability. Third, proportionately more patients in RWP had failed a prior systemic/biologic therapy (P \ .001), implying they had more challenging psoriasis and the disadvantages associated with AEs may have outweighed the therapeutic benefits of apremilast.
Overall, this study suggests that patients with psoriasis in RWP who were using apremilast expectedly reported less tolerability compared with patients in RCTs and may have experienced proportionately fewer mild-to-moderate AEs, bearing in mind that AEs were not actively elicited in RWP.
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